Therapeutic development paths for cognitive impairment in Parkinson's disease: Report of a regulatory roundtable

Journal of Parkinson's Disease

Volumn 4, Issue 4, 2014, Pages 585-589

  Eberling, Jamie ^a   Vincent, Lona ^a   Goldman, Jennifer G ^b   Weintraub, Daniel ^c   Kulisevsky, Jaime ^d   Marras, Connie ^e   Stebbins, Glenn ^b   Kieburtz, Karl ^f  

^a THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF ROCHESTER   (United States)

Author keywords

clinical trial; cognition; FDA; Parkinson's

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COGNITION; DETERIORATION; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDICATION; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HUMAN; LONG TERM CARE; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; OUTCOME ASSESSMENT; PARKINSON DISEASE; QUALITY OF LIFE; SHORT COURSE THERAPY; TREATMENT INDICATION; COGNITION DISORDERS; COMPLICATION; DISEASE COURSE; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY;

CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 84914666539     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-140385     Document Type: Article

References (27)

1. Litvan I, Goldman JG,Troster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marter K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, &Emre M(2012) Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord, 27, 349-356.
2. Petersen KF, Larsen JP, Tysnes OB, & Alves G (2009) Prognosis of mild cognitive impairment in early Parkinson disease: The Norwegian ParkWest study. JAMA, 70, 580-586.
3. Broeders M, de Bie RMA,Velseboer DC, Speelman JD, Muslimovic D, & Schmand B (2013) Evolution of mild cognitive impairment in Parkinson disease. Neurology, 18, 346-352.
4. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, & Barker RA (2009) The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain, 132, 2958-2969.
5. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, & Barker RA (2013) The CamPaIGN study of Parkinson's disease: 10 year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry, 84, 1258-1264.
6. Goldman JG, Williams-Gray C, Barker RA, Duda JE, & Galvin JE (2014) The spectrum of cognitive impairment in Lewy body diseases. Mov Disord, 29, 608-621.
7. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, & Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Archives of Neurology, 56, 303-308.
8. Marras C, Troster AI, Kulisevsky J, &Stebbins GT(2014) The tools of the trade: A state of the art "How to assess cognition" in the patient with Parkinson's disease. Mov Disord, 29, 584-596.
9. Folstein MF, Folstein SE, & McHugh PR (1975) "Minimental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12, 189-198.
10. Rosen WG,Mohs RC, & Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry, 141, 1356-1364.
11. Pagonabarraga J,Kulisevsky J, Llebaria G, Garciá-Sánchez C, Pascual-Sedano B, & Gironell A (2008) Parkinson's diseasecognitive rating scale: A new cognitive scale specific for Parkinson's disease. Mov Disord, 23, 988-1005.
12. Kalbe E, Calabrese P, Kohn N, Hilker R, Riedel O, Wittchen HU, Dodel R, Otto J, Ebersbach G, & Kessler J (2008) Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument.Parkinsonism Relat Disord, 14, 93-101.
13. Marinus J, Visser M, Verwey NA, Verhey FRJ, Middelkoop HAM, Stiggelbout AM, & Van Hilten JJ (2003) Assessment of cognition in Parkinson's disease. Neurology, 61, 1222-8.
14. Matteau E, Dupre N, Langlois M, Provencher P, & Simard M (2012) Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia. J Geriatr Psychiatry Neurol, 25, 100-106.
15. Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB,&Weintraub D (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson's disease. Neurology, 73, 1738-1745.
16. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ, Watts R, & Anderson TJ (2010) The MoCA: Well-suited screen for cognitive impairment in Parkinson disease. Neurology, 75, 1717-25.
17. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, & DuBois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord, 22, 1689-1707; quiz 1837.
18. Rosenthal E, Brennan L, Xie S, Hertig H, Milber J, Weintraub D, Karlawish J, & Siderowf A (2010) Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord, 25, 1170-1176.
19. Kulisevsky J, Fernandez de Bobadilla R, Pagonabarraga J, Martinez-Horta S, Campolongo A, Garcia-Sanchez C, Pascual-Sedano B, Rebosa-Nogue R, & Villa-Bonomo C (2013) Measuring functional impact of cognitive impairment: Validation of the Parkinson's disease cognitive functional rating scale. Parkinsonism Relat Disord, 19, 812-817.
20. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, & Weiner WJ (2010) The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol, 67, 64-70.
21. Feldman H, Sauter A, Donald A, Gelinis I, Gauthier S, Torfs K, Parys W, & Mehnert A (2001) The disability assessment for dementia scale: A 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord, 15, 89-95.
22. Weintraub D, Shea JA, Rubright JD, Karlawish J, Rick J, Goldmann R, Hurtig H, Duda JE, Xie XX, & Siderowf A (2013) Psychometric properties of the Brief Penn Daily Activities Questionnaire (PDAQ) for Parkinson's disease. (poster). MDS Congress, Sydney.
23. Mollenhauer B, Rochester L, Chen-Plotkin A, & Brooks D (2014) What can biomarkers tell us about cognition in Parkinson's disease Mov Disord, 29, 622-633.
24. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankowic J, Lang A, Langston W, Melamed D, Poewe W, Stocchi F, Tolosa E, & ADAGIO Study Investigators (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med, 361, 1268-78.
25. Naismith SL, Mowszowski L, Diamond K, &Lewis SJ (2013) Improving memory in Parkinson's disease: A healthy brain ageing cognitive training program. Mov Disord, 28, 1097-1103.
26. Sinforiani E, Banchieri L, Zucchella C, Pacchetti C, & Sandrini G( 2004) Cognitive rehabilitation in Parkinson's disease. Arch Gerontolo Geriatr Suppl, 387-391.
27. Hindle JV, Petrelli A, Clare L,&Kalbe E (2013) Nonpharmacological enhancement of cognitive function in Parkinson's disease: A systematic review. Mov Disord, 28, 1034-1049.